Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

MESOBullishCorporate Developmentsnews

High materiality9/10

Mesoblast completes Phase 3 CLBP treatment; readout expected in 2027

Aug 16, 2026, 8:37 PM EDT2 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Milestone completion reduces execution risk; RMAT designation and a potential mid-2027 BLA readout create multiple price catalysts, supported by a large addressable CLBP market and potential >$10B peak revenue.

AI summary

What happened, with direct paths to the underlying reporting

Mesoblast reports completion of patient treatment in the MSB-DR004 Phase 3 trial for rexlemestrocel-L in chronic low back pain, with 350 patients treated. The RMAT designation supports potential priority FDA review, and top-line results are due mid-2027 after the 12-month follow-up. The program targets a multibillion-dollar revenue path if approved, underscoring meaningful upside for MESO investors.

350 patients treated in MSB-DR004 Phase 3 CLBP trial.
Primary endpoint: 12-month pain reduction; trial well-powered.
RMAT designation enables priority review after BLA filing.
Top-line results expected mid-CY2027 after final 12-month follow-up.
CLBP affects 7M+ US patients; potential peak revenue >$10B.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.